Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO)
If you are the contact person for this centre and you wish to make any changes, please contact us.
Professor of Genetics at the University of Valencia and researcher of the Genomics and Health Area at the Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (Fisabio)
Professor of Genetics at the University of Valencia and researcher at the Institute of Integrative Systems Biology (I2SysBio) of the University of Valencia-CSIC
Senior Researcher at FISABIO-Dr. Peset University Hospital
Epidemiologist, researcher in the Health Services and Pharmacoepidemiology Research Area of the Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO) and Director of Gaceta Sanitaria, the scientific journal of the Spanish Society of Public Health and Health Administration (SESPAS)
The Minister of Health, Carolina Darias, today announced that face masks will no longer be compulsory indoors after Easter. The measure will come into force on 20 April. It will continue to be compulsory in public transport, health centres and residences, but the final details of the new scenario are not yet known.
The Public Health Commission has updated the Covid-19 Surveillance and Control Strategy, which will come into force on Monday 28 March. From then on, as long as indicators of healthcare utilisation are at low risk, diagnostic testing will focus on vulnerable individuals and settings and severe cases. Surveillance will focus on these groups.
In recent days, several countries have modified the quarantine times for close contacts and the isolation of infected people, while others are already considering it. Spain has announced that it will reduce these periods to 7 days, both for people who have tested positive in a test and for close contacts who require quarantine (in the case of our country, unvaccinated people).
The misleading presentation of hospitalization data, ICU admissions or deaths in vaccinated and unvaccinated persons that we are seeing these days in some media and social networks are generating confusion about the effectiveness of these preparations.
A new variant of the coronavirus causing COVID-19 has been identified in South Africa, with numerous mutations present in other variants, including Delta. Variant B.1.1.529, as it is now called, appears to be spreading rapidly in South Africa. Attached is the rapid reaction of three Spanish researchers with expertise in genomic surveillance.
A clinical trial in Brazil evaluated the effectiveness of a depression drug versus placebo in reducing the risk of hospitalisation for SARS-CoV-2 infection. Administration of 100 mg twice daily for ten days to high-risk outpatients with early diagnosis reduces the need for hospitalisation.